Avalon Pharmaceuticals, Inc. (NASDAQ: AVRX), a biopharmaceutical company, is committed to discovering, developing and commercializing superior cancer therapeutics. The company’s proprietary platform, AvalonRx®, is designed to discover and develop therapeutics for pathways that have been characterized as “undruggable” in the past. For further information, visit the Company’s web site at www.avalonrx.com.
- 17 years ago
QualityStocks
Avalon Pharmaceuticals, Inc. (NASDAQ: AVRX)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – VolitionRx (NYSE American: VNRX) Prepares Reimbursement Submission for Nu.Q Cancer Assays in France
VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced that it is preparing a reimbursement submission for its Nu.Q®…
-
QualityStocksNewsBreaks – Brand Engagement Network Inc. (NASDAQ: BNAI) Reports Warrant Exercises, Debt Conversion, and Public Warrants Update
Brand Engagement Network Inc. (NASDAQ: BNAI) announced on Wednesday that it generated approximately $1.46 million…
-
Soligenix (NASDAQ: SNGX) Positioning for Impact in Growing Rare-Disease Landscape
The World Health Organization’s recent recognition of rare diseases as a global health priority underscores…